Medicare’s Hospital Value-Based Purchasing program has not accelerated the improvement of patient experience beyond previous trends, according to a  reported this week in Health Affairs. “Instead, we found that the rate of improvements in patient experience has slowed since the program was implemented,” the authors said. “Over the entire study period, certain subsets of hospitals (such as small ones) seemed to have improved in patient experience more than other subsets (such as larger hospitals), yet even for the institutions that had greater improvement, the majority of the change occurred before implementation of the VBP program.” The study examined trends in multiple measures of patient satisfaction between 2008 and 2014. The Centers for Medicare & Medicaid Services began publicly reporting on patient-reported experience through the Hospital Consumer Assessment of Healthcare Providers and Systems survey in 2008, and tied Medicare payments directly to these measures through the VBP program in 2011. The authors said the study “adds to a growing body of literature suggesting that U.S. pay-for-performance schemes have had little to no effect on driving meaningful improvements in other patient outcomes.”

Related News Articles

Headline
The Supreme Court April 29 ruled 7-2 in favor of the Department of Health and Human Services in a case that challenged how HHS applied Congress’ formula for…
Headline
The AHA Living Learning Network is launching the Quality Exchange, a virtual collaborative for health care quality and patient safety professionals at…
News
The Centers for Medicare & Medicaid Services April 7 released finalized payment rates for calendar year 2026 Medicare Advantage and Part D plans. Payments…
Headline
The AHA today urged the Medicare Payment Advisory Commission to take specific actions on physician fee schedule payments following recommendations the…
Headline
The Centers for Medicare & Medicaid Services April 4 finalized changes to the Medicare Advantage and prescription drug programs for contract year 2026. The…
Headline
The U.S. District Court for the Eastern District of Texas March 31 ruled that the Food and Drug Administration does not have the authority to regulate…